RNA Editing for Neurodegenerative Diseases Market Size, Share, Growth and Forecast (2026 - 2036)

RNA Editing for Neurodegenerative Diseases Market Analysis and Forecast by Fact.MR

According to Fact.MR estimates, the global rna editing for neurodegenerative diseases market market was valued at USD 125.0 million in 2025. The market is projected to reach USD 151.4 million in 2026 and is expected to grow to USD 1,026.8 million by 2036, expanding at a CAGR of 21.1%. RNA Editing Therapeutics is anticipated to account for 47.0% of the product segment in 2026, while Alzheimer’s Disease is expected to remain the leading application with around 34.0% share.

Summary of RNA Editing for Neurodegenerative Diseases Market

• Market Snapshot
  • The RNA Editing for Neurodegenerative Diseases market was valued at USD 125 million in 2025.
  • By 2036, the RNA Editing for Neurodegenerative Diseases market is expected to be worth USD 1,026.82 million.
  • From 2026 to 2036, the market is projected to expand at a CAGR of 21.1%.
  • The market is projected to create an incremental opportunity of USD 875.45 million between 2026 and 2036.
  • In 2026, RNA Editing Therapeutics are expected to account for 47% of the product segment, anchored by oligonucleotide-based editors and ADAR-recruiting platforms targeting CNS indications.
  • The United States (23.5%) and Germany (22.8%) are two of the fastest-growing markets in the world.
• Demand and Growth Drivers
  • Demand is shaped by the absence of disease-modifying therapeutics for most neurodegenerative conditions, including Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal dementia, where RNA editing offers a reversible alternative to DNA-level gene editing.
  • Growth reflects intensifying investment from specialist biotechs and large pharma sponsors into CNS-targeted RNA editing programs, with Shape Therapeutics, Korro Bio, ProQR, and Wave Life Sciences advancing neurological indications into clinical development.
  • Adoption is increasing as intrathecal and engineered AAV delivery systems demonstrate clinical feasibility for CNS payloads, removing a key historical barrier to neurological RNA therapeutics.
• Product and Segment View
  • RNA Editing Therapeutics lead the product segment at 47% share in 2026, anchored by ADAR-recruiting oligonucleotides and synthetic guide RNA systems designed for CNS tissue targeting.
  • Oligonucleotide therapies represent a supporting pool at approximately 27% share in 2026, covering chemically modified editors delivered intrathecally and antisense backbones adapted for site-directed RNA editing.
  • Gene therapy delivery platforms contribute approximately 15% share in 2026, covering engineered AAV serotypes optimized for CNS tropism and lipid nanoparticle systems in early CNS development.
• Geography and Competitive Outlook
  • North America dominates the market, with the United States at a 23.5% CAGR driven by concentrated CNS-focused biotech venture capital, active FDA engagement on neurological RNA therapeutic pathways, and ALS and Huntington's disease patient advocacy ecosystems.
  • Europe is led by Germany (22.8%) and the United Kingdom (22.1%), supported by Munich, Heidelberg, Cambridge, and Oxford research clusters and strong academic neurodegeneration biology programs.
  • Asia Pacific is led by Japan (21.4%) and South Korea (20.0%), driven by national dementia research initiatives and expanding domestic RNA therapeutic pipelines. Leading players include Shape Therapeutics, Korro Bio, ProQR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Editas Medicine, Wave Life Sciences, Ionis Pharmaceuticals, Biogen, Roche, Tessera Therapeutics, and Locana.
• Analyst Opinion
  • RNA editing in neurodegenerative disease is one of the most technically ambitious and commercially consequential frontiers in biopharma. The category sits at the intersection of severe unmet medical need, mature underlying biology around genetic and RNA-level disease drivers, and rapid progress in CNS delivery technology. The commercial payoff is large: successful programs in monogenic indications like Huntington's disease or hereditary ALS will establish pricing benchmarks in the USD 300,000 to USD 700,000 per patient range, and successful expansion into idiopathic Parkinson's or Alzheimer's subsets would unlock multi-billion-dollar peak revenue. The strategic question for sponsors is how quickly CNS delivery platforms mature. Intrathecal oligonucleotides work for ALS, SMA-type indications, and Huntington's where local delivery reaches the target. Systemic delivery for brain-wide distribution remains difficult and will determine whether broader CNS indications open up in the next decade. Firms that combine RNA editing platform IP with proprietary CNS delivery capability will command the strongest competitive positions.

Why is the RNA Editing for Neurodegenerative Diseases Market Growing?

• Severe unmet clinical need in neurodegenerative diseases creates strong sponsor and payer incentive for novel mechanism therapeutics that offer disease modification rather than symptomatic management.
• CNS delivery technology is maturing rapidly, with intrathecal oligonucleotide delivery already clinically validated and engineered AAV serotypes demonstrating improved CNS tropism in clinical and preclinical programs.
• Genetic target discovery in neurodegeneration has accelerated, producing a growing library of actionable RNA-level targets in Huntington's disease, ALS, Parkinson's disease, and frontotemporal dementia.

The clinical need drives the investment thesis. Neurodegenerative diseases collectively affect tens of millions of patients globally, and disease-modifying therapeutics are largely absent across the category. Symptomatic treatments for Parkinson's, Alzheimer's, and ALS offer only modest benefit. Monogenic conditions like Huntington's disease and familial ALS have clear RNA-level targets but lack approved disease-modifying therapy. Payer willingness to fund novel mechanism therapeutics in these conditions is high because the alternative is long-term progression and high downstream care costs.

CNS delivery maturation is the technical enabler. Intrathecal oligonucleotide delivery has been validated through approvals of nusinersen in spinal muscular atrophy and tofersen in SOD1-ALS, which establishes a regulatory and clinical blueprint for RNA-based CNS therapeutics. Engineered AAV serotypes are demonstrating CNS tropism in clinical programs, and several CNS-directed delivery platforms are moving from preclinical into first-in-human trials. Each delivery breakthrough expands the set of neurodegenerative indications that RNA editing can address.

Genetic target discovery is the third driver. Large-scale genomics and RNA biology work has identified actionable targets in Huntington's disease (HTT mRNA), hereditary ALS (SOD1, C9orf72, FUS, TDP-43), Parkinson's (SNCA, LRRK2, GBA), and frontotemporal dementia (GRN, MAPT). Each actionable target becomes a potential RNA editing program, and the pipeline of candidate targets continues to expand as neurodegeneration biology matures. That growing target library supports sustained pipeline growth across the forecast period.

Segment-wise Analysis of RNA Editing for Neurodegenerative Diseases Market

• RNA Editing Therapeutics lead the product segment at 47% share in 2026, anchored by ADAR-recruiting oligonucleotides and synthetic guide RNA editors designed for CNS targeting.
• Huntington's disease and ALS dominate the indication segment in 2026, reflecting the strength of genetic target validation and the depth of active clinical pipelines.
• Intrathecal oligonucleotide delivery leads the technology segment in 2026, based on clinical validation and installed base of CNS-directed oligonucleotide infrastructure.

The market segments across product, indication, end use, technology, delivery route, and region. Product coverage includes RNA editing therapeutics, oligonucleotide-based editors, engineered RNA deaminases, CRISPR-Cas13 platforms, and CNS delivery systems. Indication coverage spans Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, frontotemporal dementia, Alzheimer's disease, and hereditary ataxias. Technology coverage includes ADAR-mediated editing, CRISPR-Cas13 RNA editing, oligonucleotide-guided RNA editing, and engineered deaminase platforms.

RNA Editing Therapeutics Lead the Product Segment

RNA editing therapeutics account for 47% of product revenue in 2026. The subsegment is anchored by ADAR-recruiting oligonucleotides that exploit endogenous editing enzymes to modify CNS disease targets, by synthetic guide RNA editors designed for intrathecal delivery, and by engineered RNA deaminase systems being advanced into clinical development.

Oligonucleotide therapies and CNS-specific delivery systems make up the second and third largest product subsegments. Chemically modified oligonucleotide backbones with improved CNS pharmacology are being combined with RNA editing activity to create hybrid product classes. Engineered AAV serotypes optimized for CNS tropism and lipid nanoparticle systems adapted for CNS delivery are growing rapidly as infrastructure categories that enable broader indication expansion.

Huntington's Disease and ALS Lead the Indication Segment

Huntington's disease and amyotrophic lateral sclerosis together represent the largest indication pool in 2026. Both conditions have well-characterized genetic targets, established clinical endpoints, and active patient advocacy communities that accelerate trial enrollment and regulatory engagement. First-wave commercial programs in these indications will establish pricing benchmarks and validate the RNA editing approach for neurodegeneration.

Parkinson's disease, frontotemporal dementia, and hereditary ataxias form a second indication pool in active clinical development. Alzheimer's disease represents a longer-term opportunity that depends on delivery platform maturation for broader CNS distribution and on continued clarification of RNA-level therapeutic targets in the disease. The overall indication mix will shift over the forecast period as delivery technology advances and new targets validate clinically.

Key Growth Drivers, Constraints, and Market Scope

• Severe unmet need, CNS delivery maturation, and expanding genetic target discovery are creating structural demand growth in neurodegeneration RNA editing.
• CNS delivery complexity, off-target editing risk in brain tissue, and long regulatory timelines constrain the speed of commercial translation.
• First-wave monogenic programs in Huntington's disease and hereditary ALS will establish pricing benchmarks and validate the category for broader expansion.

The RNA editing for neurodegenerative diseases market sits at a transformative stage. Scientific foundations in CNS RNA biology are strong, capital flows are accelerating, and first clinical candidates are advancing through trials. The key variables over the forecast period are CNS delivery platform maturation, regulatory framework clarity, and the clinical success rate of first-wave monogenic programs.

Growth Drivers

Three primary forces drive growth. First, neurodegenerative diseases represent one of the largest areas of unmet medical need in developed-market healthcare, creating strong clinical, payer, and regulatory incentive for novel mechanism therapeutics. Second, CNS delivery technology has matured enough to enable clinical translation, with intrathecal oligonucleotides validated by nusinersen and tofersen approvals and engineered AAV serotypes advancing in CNS programs. Third, expanding genetic target discovery in neurodegeneration continues to generate new actionable RNA-level targets, sustaining long-term pipeline growth across the category.

Constraints

CNS delivery remains the most significant technical constraint. Intrathecal delivery works for conditions where spinal and brainstem exposure is sufficient, but brain-wide distribution for conditions like Alzheimer's and Parkinson's remains difficult. Off-target editing in brain tissue is a safety concern that requires extensive preclinical characterization and careful clinical monitoring. Regulatory pathways for CNS RNA editing are still evolving, and clinical trial durations in slowly progressive neurodegenerative conditions extend development timelines significantly. Manufacturing at scale for chemically complex oligonucleotide editors and CNS-targeted delivery systems adds cost that compresses margins until platforms mature.

Opportunities

The largest near-term opportunity is in monogenic neurodegenerative conditions where genetic target validation is strong and clinical benefit is well-defined. First-wave programs in Huntington's disease and hereditary ALS will establish pricing benchmarks and validate the category. A second opportunity is in RNA editing platforms optimized for CNS delivery, where sponsors can build defensible platform positions by combining editing IP with proprietary CNS delivery capability. A third opportunity is in expanded indications as delivery technology matures, including broader ALS subsets, Parkinson's disease genetic subtypes, and frontotemporal dementia programs. Patient advocacy organizations in neurodegenerative diseases are unusually active, and sponsor partnerships with advocacy groups accelerate enrollment and regulatory engagement.

Regional Outlook Across Key Markets

• North America dominates the market, with the United States at a 23.5% CAGR supported by concentrated CNS-focused biotech clusters, active FDA engagement on RNA therapeutic pathways, and strong patient advocacy ecosystems in ALS and Huntington's disease.
• Europe is led by Germany (22.8%) and the United Kingdom (22.1%), anchored by Munich, Heidelberg, Cambridge, and Oxford research clusters with deep neurodegeneration biology expertise.
• Asia Pacific is led by Japan (21.4%) and South Korea (20.0%), supported by national dementia research initiatives and expanding domestic CNS therapeutic pipelines.
• France (20.7%) provides steady growth, supported by Sanofi neurology activity and INSERM-funded neurodegeneration research.

Regional performance reflects the geography of CNS-focused biotech clusters, pharma partner activity, and national neurodegeneration research priorities. North America dominates in absolute revenue and growth pace because it combines the largest venture capital pool, the most active FDA engagement, and the headquarters of most leading CNS RNA editing specialists. Europe is structurally important through neurodegeneration research strength and growing biotech clustering around Munich, Heidelberg, Cambridge, and Oxford. Asia Pacific is scaling fast from a low base, anchored by Japan's dementia research initiatives and South Korea's expanding biotech sector.

United States

The United States is the largest single-country market, with 2026 revenue of approximately USD 35.6 million and a 23.5% CAGR through 2036. The country hosts Shape Therapeutics, Korro Bio, Wave Life Sciences, Ionis Pharmaceuticals, Beam Therapeutics, and Editas Medicine, and attracts the majority of venture capital flowing into CNS RNA editing biotech. Boston, Cambridge, San Francisco, and Research Triangle Park are the primary geographic centers.

• Concentrated CNS-focused biotech headquarters in Boston and Cambridge support the largest domestic CNS pipeline globally.
• NIH funding and active FDA engagement on CNS RNA therapeutic pathways accelerate clinical translation across monogenic indications.
• Strong patient advocacy ecosystems in ALS, Huntington's disease, and Alzheimer's disease accelerate trial enrollment and regulatory engagement.

Germany

Germany records a 22.8% CAGR through 2036. Munich, Heidelberg, and Berlin support established biotech clusters, Max Planck and Helmholtz networks run strong academic neurodegeneration programs, and BioNTech's RNA therapeutic expertise extends into adjacent CNS RNA editing research. German pharma sponsors are active in partnership and licensing deals with leading RNA editing biotechs.

• Munich, Heidelberg, and Berlin biotech clusters anchor German CNS RNA therapeutic research and translation.
• Max Planck, Helmholtz, and German Center for Neurodegenerative Diseases networks run leading CNS research programs.
• BioNTech's RNA therapeutic expertise and infrastructure extend into adjacent CNS RNA editing research.

United Kingdom

The United Kingdom posts a 22.1% CAGR through 2036. Cambridge and Oxford biotech clusters have produced several CNS-focused biotechs, MRC and UK Dementia Research Institute funding supports academic neurodegeneration research, and UK pharma firms including AstraZeneca are active in CNS RNA therapeutic partnerships.

• Cambridge and Oxford biotech clusters anchor UK CNS RNA editing research and therapeutic development.
• MRC, UK Dementia Research Institute, and Wellcome Trust funding supports academic neurodegeneration research.
• AstraZeneca and other UK pharma firms are active in CNS RNA therapeutic licensing and partnership deals.

Japan

Japan is the leading Asian market for CNS RNA editing, with a 21.4% CAGR through 2036. PMDA has engaged actively on RNA therapeutic regulatory pathways, domestic pharma sponsors including Takeda, Eisai, and Daiichi Sankyo are investing in CNS RNA therapeutic partnerships, and universities in Tokyo, Osaka, and Kyoto run established neurodegeneration research programs. National dementia research initiatives direct substantial public funding into CNS therapeutic translation.

• PMDA engagement on RNA therapeutic regulatory pathways supports accelerated domestic CNS clinical translation.
• Takeda, Eisai, and Daiichi Sankyo are active in CNS RNA therapeutic partnerships with global specialists.
• National dementia research initiatives direct substantial public funding into CNS therapeutic translation.

France

France posts a 20.7% CAGR through 2036. Sanofi is actively partnering with RNA editing biotechs and building internal CNS therapeutic capability, INSERM runs strong academic neurodegeneration programs, and Paris and Lyon biotech clusters support emerging CNS-focused startups.

• Sanofi's active CNS RNA therapeutic partnership and internal program development anchors domestic demand.
• INSERM-funded academic neurodegeneration research feeds translational pipeline development.
• Paris and Lyon biotech clusters support emerging CNS-focused RNA therapeutic startup activity.

South Korea

South Korea records a 20.0% CAGR through 2036. Government precision medicine and bio-innovation programs direct public funding into RNA therapeutic research, Seoul and Daejeon support growing biotech clusters, and major domestic pharma groups are scaling CNS therapeutic activity through partnerships and internal program development.

• Government precision medicine and bio-innovation programs direct public funding into CNS RNA therapeutic research.
• Seoul and Daejeon biotech clusters support growing domestic CNS therapeutic pipeline development.
• Samsung Biologics and other Korean CDMOs are building RNA therapeutic manufacturing capacity that supports domestic CNS sponsors.

Competitive Benchmarking and Company Positioning

• Specialist leaders Shape Therapeutics, Korro Bio, and ProQR Therapeutics collectively represent the core of the RNA editing specialist category in neurodegeneration, supported by differentiated platform IP and active CNS pipelines.
• Large pharma sponsors Roche, Biogen, and Novartis participate through licensing deals and strategic partnerships rather than through internal CNS RNA editing platform development.
• Adjacent RNA therapeutic firms Wave Life Sciences, Ionis Pharmaceuticals, Beam Therapeutics, and Intellia Therapeutics bring RNA chemistry and editing expertise that is being adapted to CNS applications.

The RNA editing for neurodegenerative diseases market features emerging concentration among specialist platform holders and strategic pharma partners. Leading specialist firms control a significant share of category activity through differentiated platform IP and active CNS clinical pipelines. The market is still early enough that pipeline breadth and CNS delivery capability matter more than installed base or commercial scale, and competitive positions will shift meaningfully as clinical data from first-wave CNS trials emerges over the next 24 to 36 months.

Biogen holds a strong strategic position through its CNS commercial infrastructure, its Ionis partnership on CNS oligonucleotide programs, and its active interest in RNA editing for neurodegeneration. Roche participates through its Shape Therapeutics licensing partnership and its broader neurology portfolio. Shape Therapeutics, Korro Bio, and ProQR Therapeutics are the leading specialist biotechs in CNS RNA editing, each with differentiated platform approaches and active neurological programs. Wave Life Sciences, Beam Therapeutics, Editas Medicine, and Intellia Therapeutics participate through active programs and platform adaptation for CNS applications.

Ionis Pharmaceuticals brings complementary expertise. The company's success with antisense oligonucleotides in CNS indications, including approvals in SMA and SOD1-ALS, provides commercial infrastructure and regulatory playbook that can be extended to RNA editing applications. Tessera Therapeutics and Locana represent emerging specialist platforms focused on advanced RNA editing technologies with CNS applicability.

The competitive dynamics in CNS RNA editing favor firms with three attributes: differentiated RNA editing platform IP, proprietary CNS delivery technology, and depth of neurodegeneration expertise. Shape Therapeutics and Korro Bio lead on platform IP. Ionis and Biogen lead on CNS commercial expertise. Roche and other large pharma partners bring capital and regulatory infrastructure. The commercial winners over the next decade will combine specialist platform IP with large pharma CNS expertise and proprietary delivery capability.

Competitive Analysis

Strategic positioning is shaped by the choice between CNS platform depth and commercial scale. Specialist biotechs own editing platform IP but lack CNS commercial infrastructure. Large pharma sponsors have CNS commercial scale but depend on licensing in RNA editing technology. The partnership model between specialists and pharma sponsors works well in early CNS development but creates tension over value capture as programs approach commercialization. Firms that can demonstrate CNS clinical success while retaining economic optionality through partial licensing or co-development will set the commercial benchmarks. CNS delivery technology is the second major competitive axis, and firms with proprietary delivery systems optimized for brain distribution will command premium partnership terms.

Benchmarking Table

Recent Developments

• Shape Therapeutics advanced its CNS-directed RNAfix platform into preclinical development in 2025, targeting monogenic neurodegenerative disease targets with programs expected to enter IND-enabling studies.
• Korro Bio extended its OPERA ADAR editing platform into neurodegenerative indications in 2025, adding CNS-targeted programs to its broader pipeline.
• Roche and Shape Therapeutics expanded their licensing collaboration in 2025 to cover additional CNS targets, reflecting continued commitment to RNA editing in neurodegeneration.

Leading Companies Shaping RNA Editing for Neurodegenerative Diseases Market

• Major Players

  • Shape Therapeutics
  • Korro Bio
  • ProQR Therapeutics
  • Wave Life Sciences
  • Ionis Pharmaceuticals
  • Biogen
  • Roche

• Emerging Players

  • Beam Therapeutics
  • Intellia Therapeutics
  • Editas Medicine
  • Tessera Therapeutics
  • Locana
  • ADARx Pharmaceuticals
  • Novartis
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Vico Therapeutics

Sources and Research References

• World Health Organization (WHO) gene therapy and RNA therapeutic frameworks and publications
• U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research guidance on RNA-based and CNS therapeutics
• European Medicines Agency (EMA) guidelines on advanced therapy medicinal products and CNS therapeutics
• Shape Therapeutics, Korro Bio, ProQR Therapeutics, Wave Life Sciences, Ionis Pharmaceuticals, Biogen, and Beam Therapeutics corporate filings and investor presentations
• ClinicalTrials.gov and EU Clinical Trials Register pipeline data for CNS RNA editing programs
• Peer-reviewed CNS biology and RNA therapeutics journals including Nature Neuroscience, Nature Biotechnology, and Molecular Therapy
• Patient advocacy organization data including ALS Association, Huntington's Disease Society of America, and CHDI Foundation
• Primary interviews with biotech executives, pharma business development leads, academic neurodegeneration researchers, CNS clinical investigators, and regulatory affairs professionals

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the size of the RNA editing for neurodegenerative diseases market in 2026 and 2036?
• What CAGR is the market expected to record between 2026 and 2036?
• Which product and technology segments are projected to lead the market in 2026?
• Which neurodegenerative indication accounts for the largest share of demand?
• How does RNA editing compete against DNA-level gene editing and conventional oligonucleotide therapy in neurodegeneration?
• Which countries are the fastest-growing markets through 2036?
• Who are the leading companies in CNS RNA editing, and how are they competitively differentiated?
• How does Fact.MR estimate and validate the market forecast?

RNA Editing for Neurodegenerative Diseases Market Definition

The RNA editing for neurodegenerative diseases market covers therapeutic products, platforms, and enabling technologies that modify RNA sequences or RNA-based regulatory elements to treat central nervous system degenerative conditions, without altering the underlying genomic DNA. The scope spans ADAR-recruiting oligonucleotides, engineered RNA deaminases, CRISPR-Cas13 RNA editors, site-directed RNA editing platforms, and the CNS-specific delivery systems and research infrastructure tied to neurodegenerative applications including Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, frontotemporal dementia, and Alzheimer's disease.

RNA Editing for Neurodegenerative Diseases Market Inclusions

The market includes RNA editing therapeutic products targeting neurodegenerative conditions, including ADAR-recruiting oligos, synthetic guide RNA editors, engineered RNA deaminases, CRISPR-Cas13 RNA editors, and site-directed RNA editing platforms. It covers CNS-specific delivery systems including intrathecal oligonucleotide formulations, engineered AAV serotypes optimized for CNS tropism, and lipid nanoparticle systems adapted for CNS delivery. The scope includes therapeutic revenue, licensing and partnership revenue attributable to neurodegeneration programs, and associated CNS research infrastructure and services.

RNA Editing for Neurodegenerative Diseases Market Exclusions

The market excludes DNA-level CNS gene editing therapeutics such as CRISPR-Cas9 genome editing programs in neurodegeneration, traditional antisense oligonucleotides not designed for RNA editing, RNA interference therapeutics that do not perform direct RNA sequence modification, small molecule disease-modifying therapeutics, and protein replacement therapies. Non-CNS RNA editing programs in liver, oncology, or other tissues fall outside the scope. Preclinical-only academic research programs without commercial development activity and standalone CNS research reagents not tied to therapeutic programs are also excluded.

RNA Editing for Neurodegenerative Diseases Market Research Methodology

• Primary Research: Interviews with RNA editing biotech executives active in CNS programs, pharma business development leads in neurology licensing, academic neurodegeneration researchers, clinical investigators in CNS trials, and regulatory affairs professionals specializing in RNA-based CNS therapeutics.
• Desk Research: FDA and EMA regulatory filings for CNS RNA therapeutic programs, ClinicalTrials.gov and EU CTR pipeline data for neurodegenerative indications, venture capital funding data for CNS RNA editing biotech, company pipeline disclosures, and peer-reviewed CNS RNA biology literature.
• Market Sizing: Forward-looking model built on active CNS clinical program counts, licensing and partnership deal values tied to neurodegeneration, CNS research infrastructure spend, and probability-weighted commercial revenue projections for programs in development.
• Data Validation: Cross-checked against company financial disclosures, licensing deal announcements, patient advocacy organization data, and investigator interviews. Sensitivity testing on clinical success probability assumptions, CNS delivery feasibility scenarios, and competitive mix across RNA editing modalities.